Navigation Links
Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference
Date:1/4/2012

NEW YORK, Jan. 4, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at JP Morgan's 30th Annual Healthcare Conference, being held January 9th-12th in San Francisco, California.  Mr. Bentsur's presentation is scheduled to take place on Thursday, January 12, 2012 at 10:00 a.m. PT (1:00pm ET). 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patien
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
3. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
6. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
7. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
9. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
10. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
11. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... 1000 balances – 4 steps – One ... needs and expertly narrows down the mass of product ... even terminals. , First, select the working environment, ... readability instead) and define the accuracy – it’s really ... down the list to models that fit best with ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... 28 Beckman Coulter, Inc. (NYSE: ... Directors declared a quarterly dividend payout of seventeen ... payable on May 22, 2009 to all stockholders ... payout represents the 80th consecutive, quarterly payout of ...
... ANGELES, April 28 MMR Information Systems (OTC ... subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") provides Web-based consumer-controlled ... ) and electronic safe deposit box storage solutions ... free Personal Health Record and free surgical masks ...
... its financial results for the first quarter of fiscal 2009 ... will be hosted by management at 11 a.m. ET following ... on the company,s Web site, www.usoncology.com , ... announcement. US/Canada Dial-in #: (877) 615-1716 , Conference ...
Cached Biology Technology:MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 2MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 3MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 4US Oncology to Report 2009 First Quarter Operating Results 2
(Date:7/24/2014)... current biodiversity, the product of 3.5 billion years of ... history of life. But it may be reaching a ... literature and analysis of data published in Science ... loss and decline of animals is contributing to what ... sixth mass biological extinction event. , Since 1500, more ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... and one of the most species richness biome of ... current levels of diversity might be still underestimated. In ... the description of new endemic species of this biome ... of samples for DNA analysis. , Using a ... analysis, researchers from the University of Richmond ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A tiny new species of frog from Brazil with a heroic name 2
... The Federation of American Societies for Experimental Biology ... Research Conference (SRC): Mobile DNA in Mammalian Genomes. ... forces shaping the structure and altering functions within mammalian ... conference will explore the explosion of data from high ...
... Societies for Experimental Biology (FASEB) announces the opening ... Gastrointestinal Tract XV: Epithelia, Microbes, Inflammation and Cancer. ... and Reversible Acetylation in Signaling and Disease is ... biological functions of reversible protein acetylation are explored ...
... University chemistry professor has begun imbedding magnetic nanoparticles ... more than 40,000 Americans must replace their knee ... Samia, an assistant professor who specializes in metallic ... Science Foundation-CAREER grant to create new materials and ...
Cached Biology News:New effort to find why replacement hips and knees go bad 2
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
... Assay, 96 wells. ELISA.Specific for total MMP-3: ... No cross-reactivity with MMP-1, -2, -9. Range: ... with cell culture supernatant, serum, plasma and ... -30 C. Category: Drug Screening & ...
Biology Products: